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Abstract As an early visitor to the injured loci, neutrophil-derived human
Myeloperoxidase (hMPO) offers an attractive protein target to modulate the in-
flammation of the host tissue through suitable inhibitors. We describe a novel
methodology of using low temperature ESR spectroscopy (6 K) and FASTTM
technology to screen a diverse series of small molecules that inhibit the peroxidase
function through reversible binding to the native state of MPO. Our initial efforts to
profile molecules on the inhibition of MPO-initiated nitration of the Apo-A1 peptide
(AEYHAKATEHL) assay showed several potent (with sub-micro molar IC50s) but
spurious inhibitors that either do not bind to the heme pocket in the enzyme or retain
high ([50 %) anti oxidant potential. Such molecules when taken forward for X-ray
did not yield inhibitor-bound co-crystals. We then used ESR to confirm direct
binding to the native state enzyme, by measuring the binding-induced shift in the
electronic parameter g to rank order the molecules. Molecules with a higher rank
order—those with g-shift Rrelative C15—yielded well-formed protein-bound crystals
(n = 33 structures). The co-crystal structure with the LSN217331 inhibitor reveals
that the chlorophenyl group projects away from the heme along the edges of the
Phe366 and Phe407 side chain phenyl rings thereby sterically restricting the access
to the heme by the substrates like H2O2. Both ESR and antioxidant screens were
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used to derive the mechanism of action (reversibility, competitive substrate inhi-
bition, and percent antioxidant potential). In conclusion, our results point to a viable
path forward to target the native state of MPO to tame local inflammation.
1 Introduction
Inflammation arising from the innate defenses is a pervasive clinical parameter of
concern across atherosclerosis, diabetes, cancer, chronic kidney disease, and neuro
degeneration [1–5]. Our interest is focused on identifying and deriving the
mechanism of action (MOA) of inhibitors directed against an inflammatory target
protein derived from the innate defense cells.
Neutrophils dominate the innate defense response of the host system and, in
response to infection, perform the following actions: extravasation, phagocytosis,
degranulation of the microbicidal agents into the lysosomes, and respiratory burst of
oxyradicals and their byproducts like HOCl (a powerful antimicrobial detoxifier)
[3–6]. In addition, they also employ neutrophil extracellular traps (NETs) that
contain proteolytic and DNAses enzymes, dual acting anti-siderophore and cationic
protein, and decondensed histones [7]. A central player in all these defense
processes (with the exception of phagocytosis) is Myeloperoxidase (MPO), which
uniquely catalyzes the reaction between the chloride and hydrogen peroxide to form
hypochlorous acid (HOCl). MPO’s role in balancing and regulating the above
response toward detoxification without tissue damage is still unraveling [8–10].
MPO is implicated in atherosclerosis through its presence in advanced lesions,
oxidation of High Density Lipoproteins (HDL) (via Apo A1), its function as NO
oxidase leading to endothelial dysfunction, and by its catalytic release of the
metalloproteinases [4, 11]. MPO is a 150 KD protein, having a ferric heme as a
catalytic site covalently linked to the protein. As a catalytic pro-oxidant enzyme,
MPO presents itself as a viable upstream therapeutic target to manage the cascade of
events leading to inflammation.
Current drug discovery approaches to control MPO’s toxic response include [4,
12]
1. Inhibition of NADPH oxidase, a local source of H2O2 in the neutrophil
granules, that fuels MPO’s catalytic action;
2. Scavenging MPO’s oxidant products like HOCl;
3. Inhibition of the catalytic active Compound I with reversible inhibitors;
4. Guiding the catalytic cycle to accumulate the less potent catalytic intermediate,
Compound II; and
5. Using suicidal substrates to inactivate the enzyme.
We took an approach that focused on the inhibitor reversibly binding to the heme
pocket in the native state of the enzyme (Fe3?) as against the catalytic forms
Compound I/II in hMPO. In this model, we rationalized that the inhibitor-bound-
MPO will hinder peroxide access to the heme (a requirement for the catalytic state
generation) [13] and hence may render it dysfunctional both in its intracellular
(granular or lysosomal states) and in the extracellular (NETs or plasma bound)
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forms. Potent nitration of proteins is one among the several microbicidal pathways
used by MPO (via Compound I, Approach 3 above) for detoxifying the tissue. We
initially used this route to investigate the inhibition of MPO by a library of
compounds. However, the results from this approach were ambiguous as it was
difficult to delineate the MOA of inhibition from the antioxidant/redox process. We
reasoned that the inhibitors, in the midst of an oxidant pool of Ferric (Fe3?) and
Compound I (Fe(IV)=O), H2O2, and superoxide/singlet oxygen are either acting as
one electron donors (antioxidant pathway) or converted to a co-substrate for the
enzyme. Further, many of the potent molecules from this screening method do not
co-crystallize with the protein. To obtain direct proof of binding and to steer clear of
antioxidant-mediated-inhibition, we employed ESR, to detect direct binding of the
inhibitors to the paramagnetic iron in the heme pocket. While our work is under
progress, another group reported the use of modified hydroxamates as highly potent
(IC50 = 5 nM) and specific reversible inhibitors of the native hMPO [13]. Using
Surface plasmon resonance studies, they measured the strength of binding and
correlated it with the degree of inhibition of the enzyme. Our studies differ from the
above in two aspects. We used a novel methodology (low temperature ESR) to
screen molecules for their binding strengths. ESR was complimented with FASTTM
technology (a method of screening mixtures of small molecule fragments for
binding to the protein molecules in the crystalline state) to initiate a fragment based
drug design (FBDD) approach for the identification and confirmation of actives [14,
15]. Both ESR and antioxidant screens were then used to derive the mechanism of
action (reversibility, competitive substrate inhibition, and percent antioxidant
potential). Secondly, we identified non-substrate type of inhibitor scaffolds as
inhibitors of the native hMPO.
The current study describes our successful efforts toward identifying molecular
scaffolds that bind to the active site in the native state (confirmed with ESR and
X-ray results), which do not act via the anti oxidant pathway, and are
mechanistically competitive and reversible in binding. We used a diverse set of
molecular scaffolds for probing the binding to the MPO active site. These
compounds evolved from a SAR design of five structural scaffolds (Manuscript
describing the SAR design, syntheses, X-ray structures, a MPO-specific chemilu-
minescence method to derive the enzyme-inhibition-constants, mouse inflammation
model development, and in vivo results is under preparation).
2 Experimental Section
2.1 Reagents
For the alpha screen assay, hMPO was obtained from Biodesign (Cat # A31804H,
1.5 mg/ml). For ESR, hMPO was obtained from Athens Research and Technology
in a lyophilized from in 50 mM Sodium acetate, pH 6.0 with 100 mM NaCl at a
concentration of 1 mg/0.321 ul/vial. For the X-ray work, hMPO was purchased
from Lee Biosciences (Catalog # 426-10, St Louis, MO). AlphaScreen protein A
acceptor beads and Streptavidin-coated donor beads were obtained from
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PerkinElmer (IgG detection kit (Protein A) Cat # 6760617M). Biotinylated peptide
substrate (AEYHAKATEHL) was obtained from SynthAssist. Rabbit anti-nitroty-
rosine antibody (cat# A21285) was obtained from Molecular Probes. Superblock
buffer was from Pierce (Cat# 37535). FBS was obtained from Gibco (Cat
10091-148). 2, 20-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS, Cat#
A3219- 100 ml, concentration 1.8 mM), reagent grade H2O2 (30 % by volume, Cat
# H1009), and Potassium Persulfate (Cat # 379824-5G) were obtained from Sigma-
Aldrich. Alpha screens and ABTS decolorization assays employed sterile 96-well
plates (Corning, Cat # 3688 and #3603), respectively.
2.2 Inhibitors
A large library of compounds (n * 2500) were tested for binding to MPO to inhibit
its catalytic activity. All the compounds reported in this paper were obtained from
various commercial sources. Proprietary compounds are not included in this paper.
Inhibitors are dissolved in 100 % DMSO for the stock solution and were
appropriately diluted with 100 % DMSO or an appropriate buffer as required in
the assay. A total of n = 350 compounds were tested as inhibitors against the native
state (Fe3?) of MPO by ESR.
2.3 Crystallography
Human Myeloperoxidase and co-crystals of MPO were crystallized and analyzed
using methods similar to those described by Davey and Fenna [16, 17]. Briefly,
hanging drops of 25 mg/mL MPO, 25 mM sodium acetate pH 5.0, 50 mM NaCl,
50 mM ammonium sulfate, 2 mM calcium chloride, and 3-10 % polyethylene
glycol 8000 were set up at 21 C over reservoir solutions containing 300 mM
sodium chloride. Crystals of the space group P21 and having two MPO subunits per
asymmetric unit grew with the aid of micro-seeding as very thin plates having a
brownish orange tinge. Crystals were soaked with inhibitor compounds at a
concentration of 50 mM, in a stabilizing buffer containing 18 % polyethylene
glycol 8000, 56 mM ammonium sulfate, 2.2 mM calcium acetate, and 56 mM
HEPES pH 7.0. Co-crystals were cryo-protected in a stabilizing buffer containing
22.2 % methylpentanediol prior to flash cooling in liquid nitrogen.
Diffraction data were collected at 100 K using Synchrotron beam line 31ID at the
Advanced Photon Source (Argonne National Laboratory) and were integrated using
MOSFLM v.6.2.6 [18]. The structure was solved (Table 1 shows the details) by
rigid body refinement against the diffraction data using a starting model derived
from Protein Data Bank entry 1D7W [19]. Inhibitor binding to the MPO heme group
was indicated by appropriately shaped peaks in the Fo–Fc electron density maps.
The inhibitor was included in the model, and iterative cycles of manual model
building with COOT [20] and restrained refinement with REFMAC v5.2.0019 [21]
were used to complete the overall structure. Figures of the crystal structure were
generated using PYMOL (www.pymol.org). Mean B-factors for the inhibitor
molecules bound in each of the A- and B-subunit active sites are 27.4 and 36.1 A˚2,
respectively, which are significantly higher than the B-factors of 8.6 and 11.0 A˚2
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associated with the respective A- and B-subunit heme groups. The higher B-factors
for the inhibitor molecules could be attributed to inhibitor occupancies of less than
1.0 or to higher degrees of thermal motion associated with the inhibitors. Lower
than expected electron density peak heights were also observed for the Cl atom in
the inhibitors, which could be due to the radiation damage to this X-Ray sensitive
group.
2.4 Alpha Screen Assay
In a typical experiment, MPO (11.8 nM final concentration) in 20 mM phosphate
buffer pH 7.4, 10 % glycerol and 0.005 % gelatin (PB) is added to each well of a
multi-well plate containing 20 ll PB ± compound (final concentration of
DMSO = 0.9 %). The reaction is started by the addition of 20 ll PB containing
1.5 lM ApoAI peptide substrate, 300 lM diethylenetriaminepentaacetic acid
(DTPA), 300 lM sodium nitrite, and 30 lM H2O2. The total reaction volume is
60 ll. The plates are incubated with agitation for 45 min at RT. The reaction is
terminated with the addition of 20 ll of a stop solution containing 11.2 nM rabbit
anti-nitrotyrosine antibody (final conc. of 2.8 nM), 100 lg/ml streptavidin donor
beads, and 100 lg/ml protein A acceptor beads (final concentration of 40 lg/ml),
FBS (1.6 % final concentration) in Superblock buffer. The plates are sealed,
incubated in the dark for 1 h, and read on a Packard Fusion alpha plate reader.
2.5 ESR Binding Assay
Sodium acetate (0.1 M, with and without 100 mM NaCl according to the assay
requirement) pH 6 buffer containing 25 % n-propanol was used as the reaction
buffer for ESR. In a typical binding assay, the following are sequentially added in an
Table 1 Data collection (values in parenthesis are for the highest resolution shell of 1.71–1.62 A˚)
Space Group, P21
Cell dimensions, 92.2 A˚ 9 63.5 A˚ 9 111.2 A˚, b (beta) = 97.38
Resolution, 1.62 A˚
Rsym, 0.142 (0.814)
Mean I/rI, 4.9 (1.6)
Completeness (%), 100 (100)
Redundancy, 3.7 (3.6)
Refinement
(values in parenthesis are for the highest resolution shell of 1.662–1.620 A˚)
Resolution, 1.62 A˚
No. Reflections, 160977 (11830)
Rwork/Rfree, 0.178/0.201
R.M.S deviations
Bond lengths, 0.01 A˚
Bond angles, 1.38
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eppendorf tube: 50 ll of 20.8 lM MPO (4.6 lM final concentration) and 15 ll of
inhibitors in DMSO at 409 concentrations to the enzyme followed by 170 ll of the
buffer. After 5-min. incubation at room temperature, the entire reaction mixture
(0.235 mL) was transferred to the ESR quartz tubes. To avoid the quartz tubes
breaking during the rapid freezing cycles, the ESR tubes were initially frozen in a
1:1 Isopentane-Cyclohexane mixture cooled with dry ice powder and then
transferred to a liquid nitrogen Dewar to be queued up for ESR measurements.
The reaction mixture contained a final concentration of 6 % DMSO. ESR spectra
were recorded on a Varian E-12, X-band spectrometer equipped with an Air
Products liquid helium cryostat. The other instrument settings are as follows: sample
temperature, 5 K; n = 7 scans; t = 9.0482 GHz; microwave power, 10 dB; 579
A/Ds per point; 1.00 min. scan; time constant 0.032 s; gain:3.20E ? 3; and
Modulation amplitude 10.00 G. Magnetic fields were calibrated with an NMR
Gaussmeter.
2.6 Reversible Binding Assay
We performed the following two assays for independently confirming the
reversibility of binding. In the filtration method, hMPO stock (1.5 mg/ml) is
diluted to 5 lg/ml with 20 mM phosphate buffer pH 7.4, 10 % glycerol (no gelatin).
120 ll of this solution is mixed with an equal volume of the compounds at a
concentration of 30 lM (final concentration 10 lM), followed by mixing in the
plate and incubation for 15 min. at room temperature. 120 ll aliquot of this solution
is transferred into separate YM30 Micron filter units and centrifuged 6 min at
9000 rpm, followed by the addition of 300 ll of the buffer and further
centrifugation for 12 min. at 9000 rpm. Wash and centrifuge cycles are repeated
2 more times with 300 ll buffer, each followed by 12 min. centrifugation steps. The
protein left on the membrane is mixed with the PB buffer to a final volume of 120 ll
and subjected to Alpha screen method as described before to probe the nitration of
Apo A1 peptide substrate which is taken as a confirmation of the restoration of the
catalytic activity of the protein.
In the ESR protocol, the methodology of Hori et al. [22] was applied with
some modifications.The protocol followed is similar to the binding assay except
that a higher concentration of hMPO (9.2 lM final) is used. This is necessary as
multiple washings followed by dilutions lead to considerable loss of the enzyme
due to its retention on the membrane. After 5 min of incubation in the
eppendorf at room temperature, the contents were transferred to an Amicon
Ultra-4 tube (5 ml capacity) and filled with 4 ml of 0.1 M sodium acetate buffer
(containing 50 mM NaCl) pH 6.0. Using spin conditions of 40009g in a
swinging bucket rotor at 20 C, the samples are washed repeatedly (29)
followed with a final wash containing 1 ml of the sodium acetate buffer
(chloride free) ? 25 % n-propanol and then concentrated. The concentrated
solution ca. 300 ll is transferred to ESR quartz tubes and measured at 4 K. A
higher concentration of MPO in these reversible binding assays enabled a good
ESR signal over noise from the washed (3X) sample.
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2.7 ABTS Radical Cation Decolorization Assay to Measure the Antioxidant
Capacity
The assay was modeled after the published procedure [23]. Briefly, ABTS radical cation
was prepared by adding 100 ll of 70 mM K2S2O8 to 10 ml ABTS, followed by
vortexing and incubating at 37 C water bath for 2 h. The solution turns blue with a
strong absorbance at 734 nm (blank absorption). The MPO inhibitors were dissolved in
DMSO, and further dilutions were made in water (dilution plate: Falcon Cat. # 351172).
Trolox standards are dissolved in water. The reaction is started by adding the ABTS
radical cation solution to the MPO inhibitors or Trolox (final concentration 20 lM).
The plate is gently shaken for 1 min and then set on a bench top at room temperature
for 30 min. The plate is then read at 734 nm on a Spectromax M5. The data are
analyzed as % inhibition at 20 uM single dose treatments.
2.8 Peroxidase Inhibition Assay
Hydrogen peroxide (30 %, v/v; 9.71 M) is used with different dilutions in ice-cold
deionized water. MPO at 50 ll of 20.8 lM (4.6 lM final concentration) is
incubated with different concentrations of H2O2 in the absence and in the presence
of inhibitors (inhibitor to MPO concentration is 40:1) for 1 min and rapidly frozen
at 77 K. The inhibitors are added to MPO, incubated for 5 min prior to H2O2
addition in these reactions.
3 Results and Discussion
3.1 Inhibition of the MPO-Initiated Apo-A1 Nitration Pathway
Through a chloride independent pathway, MPO catalyzes the one electron oxidation
of nitrite ions to nitrogen dioxide radicals which then nitrosylate protein amino
acids like Tyrosine [24]. We used the Apo-A1 peptide substrate (AEYHAKATEHL)
to follow the nitration of the Tyrosine (indicated by Y in the scheme below):
MPO þ H2O2 ! Compound I
NO2 þ Compound I ! NO2 þ Compound II
Our initial experiments focused on identifying inhibitors that bind to the heme to
inhibit the above catalytic action. A representative set of inhibitors is collected in
Fig. 1a (strong binders, vide infra) and b (non binders, vide infra). The IC50s for
these compounds are indicated in Table 2. As shown in Table 2, several potent
inhibitors, with desirable IC50 (B10 lM), were found by this procedure.
Previous studies [13, 25–28] have shown that compounds inhibit the above
pathway by either coordinating with the heme iron or by scavenging the radicals
(antioxidant) or acting as substrate to Compound I. The latter two are not a desired
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route for the native state inhibition. But the predominant contribution in the above
nitrosylation inhibitory mechanism is not apparent from the observed IC50 values in
Table 2. In our studies, we focussed on avoiding the antioxidant-mediated-
inhibition by using an ABTS assay [23] to filter compounds based on a threshold of
50 % above which the compounds are classified as strong anti oxidants. Those
compounds that showed the desirable profile of IC50 B10 lM and antioxidant
capacity\50 % (Table 2 shows only a representative set) were taken forward for
the crystallization of inhibitor-bound MPO crystals. However, we had very little
success in isolating bound X-ray quality co-crystals from these compounds.
Evidently, these spurious molecules (a subset collected separately in Fig. 1b) are
acting as competitive electron donors to Compound I or II or in some cases acting as
substrates. This necessitated an alternate method to unambiguously confirm the
inhibitor binding to the protein.
























































Fig. 1 Concentration response curves from the alpha screen assay run on a representative set of the
compound library profiled for inhibition of the MPO’s catalytic nitration of Apo-A1 nitration.
a Compounds that bind to the heme (as found later with ESR), b non-binding compounds. The IC50
values for these compounds are collected in Table 2
860 B. Chavali et al.
123
Table 2 A small subset of hMPO inhibitors used to describe the mechanism of action (MOA) in terms of
their binding (IC50, lM), rank ordering from ESR, success of co-crystal growth from X-ray and percent
anti oxidant potential
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Table 2 continued
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3.2 ESR Spectra is Sensitive to Inhibitor Binding
We employed ESR, a technique that uniquely describes the putative inhibitors
binding to the heme iron in MPO. Binding induces electronic changes in the heme
active site symmetry which manifests itself in shifting the g values [22] and thus can
be used as a sensitive probe of the protein conformation. The tetrapyrrole containing
heme unit is usually planar (D4h) in the absence of interactions with the protein.
When the heme gets attached to the apo protein, the heme plane is distorted. These
distortions are brought about by the protein through covalent binding to heme [29,
30]. The geometry of the water molecules in the heme pocket also plays a role.
These distortions modulate the redox properties of the heme iron. Further distortions
(and hence further lowering of the symmetry) are expected to happen when the
inhibitor molecules enter the heme pocket to coordinate with the heme or with the
water molecules. ESR is a sensitive technique to track the effect of these structural
distortions on the d-orbital symmetry of the iron. Hence, ESR at liquid helium
temperatures was used to assess inhibitors binding to the heme. In addition, in some
of the bound complexes, the snap freezing of the reaction mixture containing the
inhibitor and enzyme enables us to capture both the bound and unbound states (on/
off states) in the solution state (vide infra).
ESR spectra of the native state of the hMPO enzyme in pH 6 buffer is rhombic at
4 K and showed a predominantly high-spin Fe3? spectrum with gX = 6.778
gY = 4.978, and gZ = 2.00 (Fig. 2).
A signal at g * 4.3 (at *1550 G Fig. 1) from high-spin rhombic Fe3?
represents a small amount of non-heme iron; it is invariably present because the
middle Kramers’ doublet (±3/2) is almost magnetically isotropic and has high
transition probability. The broad signal on the low-field side of gZ * 2 in Fig. 1 is
due to a cavity contaminant. The ESR spectrum of the native state (Fig. 1) is most
probably a representative of the resting enzyme in the phagosome where the pH is
low and the chloride concentration is high [31]. Masao-Ikeda et al. [31] studies have
Table 2 continued
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revealed that axial water coordination increases rhombicity along with a mixture of
low- and high-spin Fe3? signals. Our enzyme preparations contained 0.05 M NaCl
in sodium acetate buffer at pH 6. At these conditions, to the best of our knowledge,
there is little prior evidence of water or hydroxyl coordination to the 6th axial
position of the heme.
This spectral behavior is reflective of Fe in a distorted heme plane bonded to a
protein with a proximal histidine and a weak (distal) axial coordination by chloride
[31]. The experimental g values correspond to the spin Hamiltonian pertinent to the
high-spin ion (S = 5/2) [29].
H ¼ D S2Z  1=3 S Sþ 1ð Þ þ E=D S2X S2Y
  þ bgeS:Be ð1Þ
where D and E are the eigen values of the axial and rhombic field components, i.e.,
the symmetry of the ligand (inhibitors approaching heme in this case). In axially
symmetric systems (tetragonal symmetry with E/D = 0), the ESR behavior pre-
dominantly reveals a two line spectrum with gX = gY = 6, and gZ = 2. When the
heme lodges inside the protein, the protein side chain amino acid (histidine) ap-
proaches the heme vicinity and either binds (axially) directly to the iron in the heme
pocket. This results in the deviation from the axial symmetric environment. Thus, the
fifth ligand leads to lower (rhombic) symmetries causing the signal at g * 6 to split.
This non-tetragonal splitting of the heme is quantitated by the relationship [29],
E=D ¼ Dg=48 ð2Þ
where Dg represents the absolute difference between the gX and gY components.
Alternatively, making use of the fact that E/D maximum value = 1/3, one can
simplify the above expression as a percentage of rhombicity, R:






















Fig. 2 X-band ESR spectrum of hMPO showing the high-field and low-field signals (800–4000 G). gX,
gY and gZ represent the rhombic components of the electronic g tensor. The instrument settings are given
in the experimental section
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R ¼ Dg=16ð Þ  100%: ð3Þ
The native heme in MPO itself has an axial symmetry with small rhombic distor-
tion, reflected by gX = gY = gZ. To rank-order molecules in terms of their ability
to distort the heme pocket/plane environment, we used a ratio of total distortion in
the bound complex w.r.t. distortion seen in the native unbound enzyme:
Rrelative ¼ RboundRnativeð Þ / Rnativeð Þ  100: ð4Þ
The gZ region (*2, Fig. 2 field range 3340–3550) was not used due to the fact
that gZ is fairly insensitive to E/D, when E/D is small (i.e., nearly axial). From the
relative rhombicities of the bound and unbound complex, a measure of the strength
of binding could be derived. We have used this Rrelative (Eq. 4) as a sensitive
measure of the distortion of the native heme environment brought about by the
incoming inhibitor molecule. For the ease of classification, we have empirically
defined those with 5 B Rrelative C 2 as weak binding; 15 C Rrelative C 10 as
moderate binding; and 25 C Rrelative C 15 as strong binding (Table 2). This
classification was used to select only the moderate and strongly bound molecules
for testing the co crystal growth for the X-ray crystal structure (vide infra).
No other iso forms of MPO are observed under these conditions. No low-spin
signals are seen. Previous studies on the bovine MPO identified both the high- and
low-spin signals at 77 K [22]. However, the authors did not report the concentra-
tions of the enzyme used in those ESR studies. We could not reproduce this ESR
behavior in our batches of hMPO obtained from the vendor. The ESR signal
intensity of the hMPO (at a concentration 23.07 uM) decreases, as the temperature
is raised from 5 to 77 K. This decrease at a higher temperature (77 K relative to
5 K), however, is not accompanied by the appearance of low-spin signals, i.e., no
evidence of temperature dependence in the spin state equilibrium could be detected.
We henceforth used 4–7 K for all our binding studies in ESR.
We were justified in using ESR to confirm binding when we found that many of
the compounds which were considered potent inhibitors (IC50 B10 lM) from the
alpha screen assay (Table 2; Fig. 1b) did not affect the ESR spectra of native hMPO
as can be seen in the Fig. 3a. In contrast, when the putative inhibitors bind to MPO,
the ESR signals at gX and gY (800–1450 G) were broadened or even split into two
components, signifying the formation of bound complexes (Fig. 3b). In the spectra
of the some of the bound-complexes, there is still a significant proportion of the
unbound enzyme. This enables one to calculate the percent or proportion of the
bFig. 3 X-band ESR spectra in the low-field region (800–1450 G) is a sensitive measure of the heme
plane distortions on binding. a Indicates absence of binding of the structurally different scaffolds of
compounds to the heme iron as indicated by the non-variance of the gX and gY signals. The native hMPO
signal is shown in bold black as a visual aid to depict the non shifting of g values of the native enzyme
with the addition of purported inhibitors. b Significant shifts in the ESR resonances on binding in the gX
and gY regions. A majority of the inhibitors shift the native hMPO signal in the positive side (difference
between bound versus unbound g values is positive, Dg[ 0) due to different distortions on the heme
plane symmetry. c LSN17948 binding accompanied by greater/positive Dg, i.e., 30 % of the enzyme is
unbound while 70 % is bound. The reaction volume in the ESR tube is 235 ll. MPO 50 ll (23.07 lM
final), 15 ll inhibitor in 100 % DMSO, Inhibitor:MPO ratio is 40:1. DMSO final concentration is 6 %.
buffer 170 ll (0.1 M Sodium acetate containing 100 mM NaCl pH 6 ? 25 % n-propanol)
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bound versus the unbound enzyme complex (Fig. 3c). The g values of the bound
complexes are collected in Table 3.
For ESR, we used inhibitor at 409 concentration to the enzyme. In some cases
when this concentration is lowered to 49, the proportion of the bound versus
unbound changed. This could be, in part, due to the fact that since the inhibitor-
protein interactions are largely non-covalent and weak, some of the displaced water
molecules in the heme environment now return to restore the symmetry and thereby
affect the bound:unbound ratios. Alternatively, since DMSO (used for dissolving the
inhibitor used at 6 % final concentration) also competes for the binding with the
heme, the inhibitor-induced distortion (and hence the bound:unbound ratio) is
changed. Since we have used ESR mainly in binary mode (to detect the presence or
absence of binding) only, these dilution-induced changes in the proportion of the on/
off states did not change our end points.
4 Solution State ESR Results are Confirmed with X-ray Crystal
Structures
To test whether the solution state results hold well in the solid state and further
to decrease the incidence of unbound crystals, we then attempted to co-crystallize
the enzyme with the moderate (15 C Rrelative C 10) and strong binding (25 C
Rrelative C 15) series of compounds. In all the cases, we obtained high-quality
Table 3 Electronic g values of a representative set of the bound complexes
S. No. LSN gX gY Dg
1 17,948 6.995 4.739 2.256
2 87,637 6.917 4.827 2.09
3 23,500 6.789 4.914 1.875
4 131,429 6.559 5.215 1.344
5 106,019 7.023 4.713 2.31
6 811,183 6.924 4.809 2.115
7 2,303,506 6.9749 4.799 2.1759
8 2,944,556 7.0681 4.7601 2.308
9 2,975,402 7.006 4.735 2.271
10 2,993,636 6.976 4.793 2.183
11 217,331 6.901 4.819 2.082
12 3,019,807 6.948 4.773 2.175
13 3,023,528 7.036 4.725 2.311
14 2,976,159 7.007 4.705 2.302
15 3,016,204 7.023 4.725 2.298
16 3,014,727 7.007 4.739 2.268
The gZ is *2.00 for all the complexes. Dg is the absolute difference between gX and gY
Due to low S/N ratio in the high-field region (weak signal on a high cavity background at 5 K), gZ value is
not accurately determined
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Fig. 4 Binding mode of the inhibitor LSN217331 to the MPO active site. Carbon, oxygen, nitrogen,
chlorine, and iron atoms are colored yellow, red, blue, green and orange, respectively. Close
intermolecular contacts are indicated by dashed green lines with distances labeled in A˚. The protein
backbone is displayed as a yellow ribbon diagram, with side chains of key residues modeled as sticks. Fo–
Fc electron density map, contoured at 3 r is displayed as gray mesh























Fig. 5 X-band ESR spectra (800–1450 G) depicting the reversible nature of the inhibitor binding to
hMPO. Only a representative example (LSN87637) is shown. After incubation of the compound with
hMPO for 5 min, the bound complex was washed with buffer ± chloride on an Amicon desalting tube
followed by concentration to 250 ll for ESR measurements
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co-crystals (n = 33). In each of these cases, the compounds were located inside the
heme pocket and are found to bind either directly to the heme iron or to the side
chains via the water molecules.
The crystal structure of 217331 bound to MPO (Fig. 4a, b) reveals a large
number of specific interactions between the inhibitor and enzyme, thus providing a
clear structural rationale for the inhibitory mechanism. The compound hydroxyl
group makes close direct contacts to the heme iron ion (3.1 A˚), the Gln91 side chain
amide nitrogen (3.2 A˚) and the His95 imidazole NE2 (2.7 A˚). These non-bonded
contact distances are consistent with the hydrogen bonds to the side chains and a
favorable dipole interaction with the iron ion. The isoxazole O atom also contacts
the Gln91 side chain amide nitrogen (3.1 A˚), while the ring N atom makes contacts
of 3.1 and 3.4 A˚ with the two methylene carbon atoms from the Glu242 side chain.
One side of the isoxazole ring contacts the gamma and delta methylene C atoms of
Arg239 in a nearly parallel orientation, while the other side lies against the heme
prosthetic group at an angle of approximately 508, with the CH contacting the
porphyrin at 3.2 A˚. The chlorophenyl group projects away from the heme along the
edges of the Phe366 and Phe407 side chain phenyl rings. Occupation of this space
by the inhibitor would sterically block peroxide and co-substrates (e.g., chloride)
from reacting at the heme center of the active site. Indeed, the inhibitor sterically
blocks both the peroxide binding site between the iron ion and His95 and the halide
binding site near the Gln91 side chain amide [16].
4.1 MOA
4.1.1 Reversible Binding
Since the gX and gY regions are very sensitive to the binding of compounds in the
heme pocket, we next assessed the reversibility of the binding of these compounds.
We used two methods (Filtration and ESR) to independently verify the reversibility
of the binding. In every case of the strong and moderately strong binders tested, the
shifted ESR spectra of the bound complexes return to the native unbound state after
washing. Figure 5 shows a representative example from a moderately strong binder
(LSN87637) series.
bFig. 6 A X-band ESR spectra (800–1450 G) of hMPO exposed to different concentrations of H2O2. As
the H2O2 concentration (label inset) increases, the gX and gY signals (arrows indicate the direction of
change) decrease with a corresponding increase in gintermediate = 6, i.e., the rhombic pattern (gX, gY, and
gZ) gradually changes into gintermediate (axial). B Inhibitor LSN 17948 (15 ll in 100 % DMSO) is added to
hMPO (50 ll) before H2O2 (555 lM) is introduced in the reaction mixture. The spectrum is unchanged
and no gintermediate signal is seen. In B, a and b are taken from A and shows decay (down arrows) of gX and
gY in the presence of 555 lM H2O2, the sign * indicates the growth of signal corresponding to
denaturation, while c shows the absence of peroxide-induced decay in the presence of 17948 (the binding-
induced g-shifts are indicated with horizontal arrows). The reaction volume in the ESR tube is 235 ll.
hMPO 50 ll (23.07 lM final), 15 ll of H2O2 at the indicated concentrations, buffer 170 ll (0.1 M
Sodium acetate containing 100 mM NaCl pH 6 ? 25 % n-propanol)
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4.1.2 Substrate (H2O2) Inhibition
We used ESR to gain additional insights on the competitive nature of the
compounds to inhibit peroxidase action, a key requirement for our native state
binders. Since ESR and X-ray have clearly established the binding of the
compounds in the vicinity of the heme, we focussed on the mode of action of these
compounds (with moderate and strong Rrelative) to classify the MOA.
Using heme-H2O2 systems, several studies have tracked and characterized the
protein and hydroperoxyl radicals with concomitant formation of ferryl (Fe=O)3?
species [32, 33]. In our studies, we focused only at the high-spin region (g * 6)
ignoring the g * 2 region where free radicals dominates [33].
Figure 6A shows the spectral changes in the low-field region of the native
enzyme as H2O2 is varied. As the peroxide concentration increases, the gX and gY
signals drop down in intensity with a concomitant increase in the g * 6 region
(B value * 1050 G). A similar behavior is reported in the presence of denaturing
agent like guanidine HCl [34]. A likely explanation for these effects is the snapping
of the covalent (via the axial histidine) and non-covalent (hydrogen bonds and other
van der Wall contacts) interaction-driven control by the protein on the heme
conformation resulting in the tetrapyrrole unit returning to its near planar (higher
symmetry) state. This is a dynamic reversible process with a threshold, above
which, the heme with its restored planarity, is ejected from the enzyme [35]. The
ESR spectrum of MPO in the presence of H2O2 indicates that the rhombicity
(gX = gY = gZ) is gradually replaced with more axial symmetry (gX = gY, and gZ).
We then added the inhibitors (with 25 C Rrelative C 10) prior to the introduction
of H2O2 and followed the ESR changes in this region. In the presence of the bound
inhibitors, these changes are prevented (Fig. 6c) even at very high concentrations of
H2O2 (555 lM, hMPO: H2O2 1:20 Fig. 6b), and the spectrum is identical to the
native human MPO (albeit shifted due to inhibitor binding). The native gX * 6.778
signal does not go down in intensity. In contrast, Forbes et al. [13] showed that the
MPO-bound hydroxamates are metabolized by MPO in the presence of H2O2. The
presence of bound inhibitors inside the heme pocket blocks the entry of H2O2 (as
seen in the co-crystal structures above) and prevents the denaturation of the enzyme.
It has been reported [4] that H2O2[50 lM causes enzyme denaturation and the new
ESR signal at g = 6 (indicated by ‘*’ in Fig. 6b) is a probable fingerprint of that
process. The absence of these spectral changes in the presence of bound inhibitors
clearly indicates that the access of H2O2 into the heme pocket either at the gate or to
the 6th axial coordination site (distal side) is prevented by these inhibitors. We
found that DMSO can also mimic this process of restricting peroxide access and
coordination to the heme. In order to differentiate the inhibitor role from DMSO, we
used hydroxamic acid inhibitors which are water soluble and found these to bind to
the enzyme and prevent the peroxide-induced changes on the enzyme even in the
absence of DMSO.
In conclusion, the results represent a comprehensive analysis of the electronic
structural changes of MPO induced by compound libraries of different scaffolds.
Using low temperature ESR, our studies provided several lead molecules (for e.g.,
LSN 17948, LSN294456, LSN87637, LSN2975402, etc.) with the following traits:
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• Inhibitor of the MPO enzyme in its catalytic state;
• Reversible in its action;
• Well defined binding mode as shown by inhibitor-bound X-ray crystal
structures;
• MOA dominated by inhibitor binding to the active site and preventing the access
of the heme to incoming H2O2 rather than acting as an anti oxidant;
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